索磷布韦/维帕他韦/伏西瑞韦在印度用于索磷布韦治疗无应答的基因3型丙型肝炎病毒感染的应用。
Use of Sofosbuvir/Velpatasvir/Voxilaprevir for Sofosbuvir Nonresponder Genotype 3 HCV Infection in India.
作者信息
Tiwari Prachi, Katiyar Harshita, Rai Praveer, Goel Amit
机构信息
Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
出版信息
J Clin Exp Hepatol. 2022 Mar-Apr;12(2):669-671. doi: 10.1016/j.jceh.2021.06.023. Epub 2021 Jul 3.
Abstract
In India, hepatitis C virus (HCV) infection is treated with sofosbuvir in combination with NS5A inhibitor (Daclatasvir, Ledipasvir, or Velpatasvir). A small proportion of them fail to achieve sustained virological response at 12 weeks (SVR12) and need retreatment. Triple-drug combination (Sofosbuvir/Velpatasvir/Voxilaprevir) is one of the options for retreatment. Here we describe a patient with cirrhosis and genotype 3a infection who was successfully treated with a triple-drug combination after relapse with two courses of Sofosbuvir-containing regimens.
摘要
在印度，丙型肝炎病毒（HCV）感染采用索磷布韦联合NS5A抑制剂（达卡他韦、来迪派韦或维帕他韦）进行治疗。其中一小部分患者在12周时未能实现持续病毒学应答（SVR12），需要重新治疗。三联药物组合（索磷布韦/维帕他韦/伏西瑞韦）是重新治疗的选择之一。在此，我们描述了一名患有肝硬化且感染基因3a型的患者，该患者在含索磷布韦方案的两个疗程复发后，采用三联药物组合成功治愈。
相似文献
1
Use of Sofosbuvir/Velpatasvir/Voxilaprevir for Sofosbuvir Nonresponder Genotype 3 HCV Infection in India.索磷布韦/维帕他韦/伏西瑞韦在印度用于索磷布韦治疗无应答的基因3型丙型肝炎病毒感染的应用。
J Clin Exp Hepatol. 2022 Mar-Apr;12(2):669-671. doi: 10.1016/j.jceh.2021.06.023. Epub 2021 Jul 3.
2
Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus Retreatment in Difficult-to-treat Patients: A Real-life Observational Study from India.索磷布韦/维帕他韦/伏西瑞韦用于难治性患者丙型肝炎病毒再治疗：来自印度的一项真实世界观察性研究
J Clin Exp Hepatol. 2024 Mar-Apr;14(2):101314. doi: 10.1016/j.jceh.2023.101314. Epub 2023 Dec 9.
3
Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.索磷布韦-维帕他韦-伏西瑞韦用于卢旺达既往直接抗病毒治疗失败的慢性丙型肝炎病毒感染患者再治疗的安全性和有效性（SHARED-3）：一项单臂试验
Lancet Gastroenterol Hepatol. 2022 Jun;7(6):542-551. doi: 10.1016/S2468-1253(21)00399-X. Epub 2022 Mar 3.
4
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.索磷布韦、维帕他韦和沃西拉韦治疗既往 HCV 感染。
N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512.
5
Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.索磷布韦/维帕他韦/沃西西拉韦：慢性丙型肝炎治疗药物。
Drugs. 2018 Apr;78(5):577-587. doi: 10.1007/s40265-018-0895-5.
6
Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.索磷布韦-维帕他韦-沃西拉帕维与利巴韦林联用或不联用治疗直接作用抗病毒药物经治的慢性丙型肝炎病毒基因型 1 感染患者。
Hepatology. 2017 Jun;65(6):1803-1809. doi: 10.1002/hep.29130. Epub 2017 May 3.
7
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.在 POLARIS-1 开放性标签子研究中，对先前接受过 NS5A 抑制剂治疗的慢性丙型肝炎病毒患者进行索磷布韦-维帕他韦-沃西拉韦的延迟治疗。
Lancet Gastroenterol Hepatol. 2018 Aug;3(8):559-565. doi: 10.1016/S2468-1253(18)30118-3. Epub 2018 May 31.
8
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.索磷布韦/维帕他韦/伏西瑞韦治疗既往接受过 DAA 治疗的慢性丙型肝炎患者的有效性和安全性。
J Hepatol. 2019 Oct;71(4):666-672. doi: 10.1016/j.jhep.2019.06.002. Epub 2019 Jun 14.
9
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.在真实世界中，对失败于 NS5A 抑制剂的 HCV 患者进行耐药指导的再治疗具有很高的疗效。
J Hepatol. 2019 Nov;71(5):876-888. doi: 10.1016/j.jhep.2019.06.022. Epub 2019 Jul 4.
10
Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection.索磷布韦-维帕他韦-沃西拉帕利治疗 12 至 17 岁 HCV 感染青少年。
Hepatology. 2022 Aug;76(2):445-455. doi: 10.1002/hep.32393. Epub 2022 Mar 1.
引用本文的文献
1
Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus Retreatment in Difficult-to-treat Patients: A Real-life Observational Study from India.索磷布韦/维帕他韦/伏西瑞韦用于难治性患者丙型肝炎病毒再治疗：来自印度的一项真实世界观察性研究
J Clin Exp Hepatol. 2024 Mar-Apr;14(2):101314. doi: 10.1016/j.jceh.2023.101314. Epub 2023 Dec 9.
2
Hepatitis C Retreatment With First-Line Direct Acting Antiviral Drugs.使用一线直接作用抗病毒药物进行丙型肝炎再治疗
J Clin Exp Hepatol. 2023 Sep-Oct;13(5):736-741. doi: 10.1016/j.jceh.2023.03.007. Epub 2023 Mar 24.
本文引用的文献
1
Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C.直接作用抗病毒治疗失败的慢性丙型肝炎患者的真实世界再治疗结局。
J Med Virol. 2021 Aug;93(8):4982-4991. doi: 10.1002/jmv.26971. Epub 2021 Apr 13.
2
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C.意大利 VIRONET-C 网络中丙型肝炎病毒基因型 3 感染患者的耐药分析和治疗结果。
Liver Int. 2021 Aug;41(8):1802-1814. doi: 10.1111/liv.14797. Epub 2021 Feb 8.
3
Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.使用8周泛基因型达卡他韦和减量索磷布韦治疗晚期肾衰竭患者的急性丙型肝炎
Nephrol Dial Transplant. 2021 Sep 27;36(10):1867-1871. doi: 10.1093/ndt/gfaa187.
4
Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.在公共医疗保健环境中，使用通用直接作用抗病毒药物进行去中心化护理，以管理慢性丙型肝炎。
J Hepatol. 2019 Dec;71(6):1076-1085. doi: 10.1016/j.jhep.2019.07.006. Epub 2019 Jul 17.
5
Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures.直接作用抗病毒药物治疗失败的丙型肝炎病毒感染者的再治疗。
Semin Liver Dis. 2019 Jul;39(3):354-368. doi: 10.1055/s-0039-1687823. Epub 2019 Apr 30.
6
Burden of hepatitis C virus infection in India: A systematic review and meta-analysis.印度丙型肝炎病毒感染负担：系统评价和荟萃分析。
J Gastroenterol Hepatol. 2019 Feb;34(2):321-329. doi: 10.1111/jgh.14466. Epub 2018 Sep 26.
7
Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min.达卡他韦与低剂量索磷布韦：一种用于估算肾小球滤过率<30 mL/min的丙型肝炎患者的有效泛基因型治疗方案。
Nephrology (Carlton). 2019 Mar;24(3):316-321. doi: 10.1111/nep.13222.
8
Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.慢性丙型肝炎病毒感染者直接抗病毒治疗后耐药相关替代的模式。
Gastroenterology. 2018 Mar;154(4):976-988.e4. doi: 10.1053/j.gastro.2017.11.007. Epub 2017 Nov 13.
9
Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.使用直接作用抗病毒药物治疗慢性基因3型丙型肝炎病毒感染：印度的经验。
Indian J Gastroenterol. 2017 May;36(3):227-234. doi: 10.1007/s12664-017-0763-3. Epub 2017 Jun 28.
10
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.索磷布韦、维帕他韦和沃西拉韦治疗既往 HCV 感染。
N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512.
Zotero 插件